Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Response to empirical anti-tuberculosis treatment in patients with sputum smear-negative pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 845s Year: 2006
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Rifampicin and INH monoresistance prevalence among Iraqi smear positive pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Sputum smear negative pulmonary tuberculosis (PTB) – when should the treatment be started? Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Treatment outcomes of smear positive pulmonary tuberculosis cases Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005
Combined collapse therapy in the treatment of cavitary pulmonary tuberculosis (CPTB) Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
To determine the acquired resistance of mycobacterium tuberculosis by culture to 1st line anti-tuberculous drugs in non responding smear positive patients who have taken category 1 Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Treatment results of cases of severe pulmonary tuberculosis with using rifabutin Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Value of bronchoscopic specimens for the diagnosis of sputum smear negative tuberculosis in high burden multidrug resistant tuberculosis setting Source: Annual Congress 2012 - Tuberculosis: invasive diagnostic and therapeutic interventions Year: 2012
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011